MedPath

Fludarabine Phosphate

These highlights do not include all the information needed to use Fludarabine Phosphate safely and effectively. See full prescribing information for Fludarabine Phosphate. Fludarabine Phosphate Injection, for intravenous use only Initial U.S. Approval 1991

Approved
Approval ID

8039c2e3-ffe5-3997-e053-2991aa0ad9d0

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 14, 2023

Manufacturers
FDA

Areva Pharmaceuticals

DUNS: 833189835

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Fludarabine Phosphate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code59923-604
Application NumberANDA090724
Product Classification
M
Marketing Category
C73584
G
Generic Name
Fludarabine Phosphate
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateFebruary 14, 2023
FDA Product Classification

INGREDIENTS (4)

SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
FLUDARABINE PHOSPHATEActive
Quantity: 25 mg in 1 mL
Code: 1X9VK9O1SC
Classification: ACTIB

Drug Labeling Information

BOXED WARNING SECTION

LOINC: 34066-1Updated: 1/24/2019

WARNING: CNS TOXICITY, HEMOLYTIC ANEMIA, AND PULMONARY TOXICITY

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Fludarabine Phosphate - FDA Drug Approval Details